^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ACVR1 inhibitor

    Related drugs:
    6d
    FALKON: A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (clinicaltrials.gov)
    P2, N=113, Completed, Clementia Pharmaceuticals Inc. | Recruiting --> Completed
    Trial completion
    |
    ACVR1 (Activin A Receptor Type 1)
    11d
    Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts (clinicaltrials.gov)
    P4, N=268, Not yet recruiting, SWOG Cancer Research Network
    New P4 trial
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)
    11d
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • Ojjaara (momelotinib)
    11d
    Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1/2, N=160, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Vonjo (pacritinib)
    26d
    A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) (clinicaltrials.gov)
    P2, N=78, Recruiting, Swedish Orphan Biovitrum | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Vonjo (pacritinib)
    2ms
    Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms (clinicaltrials.gov)
    P2, N=27, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • Inqovi (decitabine/cedazuridine) • Vonjo (pacritinib)
    2ms
    Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, United Lincolnshire Hospitals NHS Trust
    New P2 trial
    |
    Ojjaara (momelotinib) • bomedemstat (MK-3543)
    2ms
    GFM-VEXAS-MMB: Momelotinib in VEXAS syndrome (2024-519779-24-00)
    P1/2, N=57, Recruiting, Groupe Francophone Des Myelodysplasies
    New P1/2 trial
    |
    Ojjaara (momelotinib)
    2ms
    Momelotinib During and After HCT in Myelofibrosis (clinicaltrials.gov)
    P1, N=28, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    Ojjaara (momelotinib)
    2ms
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Dec 2027 --> Mar 2028
    Trial primary completion date
    |
    azacitidine • Ojjaara (momelotinib)
    2ms
    MDS: Pacritinib With Aza for Upfront Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=25, Not yet recruiting, Thomas Jefferson University
    New P1/2 trial
    |
    azacitidine • Vonjo (pacritinib)
    3ms
    Pharmacologic Inhibition of JAK1/2 Potentiates Aminoglycoside-Induced Ototoxicity. (PubMed, Otol Neurotol)
    JAK1 and JAK2 inhibition worsens cochlear damage in mice exposed to aminoglycosides.
    Journal
    |
    JAK1 (Janus Kinase 1) • CDH2 (Cadherin 2) • CDH3 (Cadherin 3) • CDH23 (Cadherin Related 23)
    |
    Ojjaara (momelotinib)